{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T18:34:47Z","timestamp":1781548487272,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13075-015-0717-z","type":"journal-article","created":{"date-parts":[[2015,8,10]],"date-time":"2015-08-10T13:35:24Z","timestamp":1439213724000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritis"],"prefix":"10.1186","volume":"17","author":[{"given":"Luisa","family":"Lindenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Spengler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Dorner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksej L","family":"Maslyanskiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey V","family":"Lapin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena I","family":"Ilivanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Martinez-Gamboa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Bastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Wittenborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Egerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd-R","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Feist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,8,13]]},"reference":[{"key":"717_CR1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.autrev.2004.09.002","volume":"4","author":"Y Alamanos","year":"2005","unstructured":"Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev. 2005;4:130\u20136.","journal-title":"Autoimmun Rev"},{"key":"717_CR2","first-page":"621","volume":"31","author":"VP Bykerk","year":"2013","unstructured":"Bykerk VP, Keystone EC, Kuriya B, Larche M, Thorne JC, Haraoui B. Achieving remission in clinical practice: lessons from clinical trial data. Clin Exp Rheumatol. 2013;31:621\u201332.","journal-title":"Clin Exp Rheumatol"},{"key":"717_CR3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/ard.2006.061002","volume":"66","author":"JS Smolen","year":"2007","unstructured":"Smolen JS, Keystone EC, Emery P, Breedveld FC, Betteridge N, Burmester GR, et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:143\u201350.","journal-title":"Ann Rheum Dis"},{"key":"717_CR4","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492\u2013509.","journal-title":"Ann Rheum Dis"},{"key":"717_CR5","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.18553\/jmcp.2012.18.s4-c.1","volume":"18","author":"JA Singh","year":"2012","unstructured":"Singh JA, Cameron DR. Summary of AHRQ\u2019s comparative effectiveness review of drug therapy for rheumatoid arthritis (RA) in adults--an update. J Manag Care Pharm. 2012;18:S1\u201318.","journal-title":"J Manag Care Pharm"},{"key":"717_CR6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040362","volume":"7","author":"G Ferraccioli","year":"2012","unstructured":"Ferraccioli G, Tolusso B, Bobbio-Pallavicini F, Gremese E, Ravagnani V, Benucci M, et al. Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis. PLoS One. 2012;7, e40362.","journal-title":"PLoS One"},{"key":"717_CR7","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3899\/jrheum.110610","volume":"39","author":"MM Soliman","year":"2012","unstructured":"Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DP, Ashcroft DM, et al. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register. J Rheumatol. 2012;39:240\u20136.","journal-title":"J Rheumatol"},{"key":"717_CR8","doi-asserted-by":"crossref","first-page":"386148","DOI":"10.1155\/2014\/386148","volume":"2014","author":"CI Daien","year":"2014","unstructured":"Daien CI, Morel J. Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine. Mediators Inflamm. 2014;2014:386148.","journal-title":"Mediators Inflamm"},{"key":"717_CR9","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","volume":"70","author":"MH Buch","year":"2011","unstructured":"Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dorner T, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:909\u201320.","journal-title":"Ann Rheum Dis"},{"key":"717_CR10","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/rheumatology\/kep314","volume":"48","author":"L Quartuccio","year":"2009","unstructured":"Quartuccio L, Fabris M, Salvin S, Atzeni F, Saracco M, Benucci M, et al. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology. 2009;48:1557\u20139.","journal-title":"Rheumatology"},{"key":"717_CR11","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.autrev.2010.07.006","volume":"9","author":"M Benucci","year":"2010","unstructured":"Benucci M, Manfredi M, Puttini PS, Atzeni F. Predictive factors of response to rituximab therapy in rheumatoid arthritis: What do we know today? Autoimmun Rev. 2010;9:801\u20133.","journal-title":"Autoimmun Rev"},{"key":"717_CR12","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/ard.2006.062505","volume":"66","author":"E Toubi","year":"2007","unstructured":"Toubi E, Kessel A, Slobodin G, Boulman N, Pavlotzky E, Zisman D, et al. Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:818\u201320.","journal-title":"Ann Rheum Dis"},{"key":"717_CR13","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3899\/jrheum.111488","volume":"40","author":"A Vancsa","year":"2013","unstructured":"Vancsa A, Szabo Z, Szamosi S, Bodnar N, Vegh E, Gergely L, et al. Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion. J Rheumatol. 2013;40:565\u201371.","journal-title":"J Rheumatol"},{"key":"717_CR14","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1136\/annrheumdis-2011-200421","volume":"71","author":"A Willemze","year":"2012","unstructured":"Willemze A, Bohringer S, Knevel R, Levarht EW, Stoeken-Rijsbergen G, Houwing-Duistermaat JJ, et al. The ACPA recognition profile and subgrouping of ACPA-positive RA patients. Ann Rheum Dis. 2012;71:268\u201374.","journal-title":"Ann Rheum Dis"},{"key":"717_CR15","doi-asserted-by":"crossref","first-page":"R132","DOI":"10.1186\/ar3070","volume":"12","author":"K Steendam Van","year":"2010","unstructured":"Van Steendam K, Tilleman K, De Ceuleneer M, De Keyser F, Elewaut D, Deforce D. Citrullinated vimentin as an important antigen in immune complexes from synovial fluid of rheumatoid arthritis patients with antibodies against citrullinated proteins. Arthritis Res Ther. 2010;12:R132.","journal-title":"Arthritis Res Ther"},{"key":"717_CR16","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00296-009-1343-3","volume":"31","author":"X Qin","year":"2011","unstructured":"Qin X, Deng Y, Xu J, Li TJ, Li S, Zhao JM. Meta-analysis: diagnostic value of serum anti-mutated citrullinated vimentin antibodies in patients with rheumatoid arthritis. Rheumatol Int. 2011;31:785\u201394.","journal-title":"Rheumatol Int"},{"key":"717_CR17","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1002\/art.23763","volume":"58","author":"A Ioan-Facsinay","year":"2008","unstructured":"Ioan-Facsinay A, Willemze A, Robinson DB, Peschken CA, Markland J, van der Woude D, et al. Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum. 2008;58:3000\u20138.","journal-title":"Arthritis Rheum"},{"key":"717_CR18","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s12291-012-0272-1","volume":"28","author":"WE Zahran","year":"2013","unstructured":"Zahran WE, Mahmoud MI, Shalaby KA, Abbas MH. Unique correlation between mutated citrullinated vimentine IgG autoantibodies and markers of systemic inflammation in rheumatoid arthritis patients. Indian J Clin Biochem. 2013;28:272\u20136.","journal-title":"Indian J Clin Biochem"},{"key":"717_CR19","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.3899\/jrheum.101086","volume":"38","author":"A Svard","year":"2011","unstructured":"Svard A, Kastbom A, Soderlin MK, Reckner-Olsson A, Skogh T. A comparison between IgG- and IgA-class antibodies to cyclic citrullinated peptides and to modified citrullinated vimentin in early rheumatoid arthritis and very early arthritis. J Rheumatol. 2011;38:1265\u201372.","journal-title":"J Rheumatol"},{"key":"717_CR20","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham 3rd CO, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569\u201381.","journal-title":"Arthritis Rheum"},{"key":"717_CR21","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.rdc.2009.10.001","volume":"35","author":"J Fransen","year":"2009","unstructured":"Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am. 2009;35:745\u201357. vii\u2013viii.","journal-title":"Rheum Dis Clin North Am"},{"key":"717_CR22","unstructured":"van Riel PL. The development of the disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28). Clin Exp Rheumatol. 2014;32 5 Suppl 85:S-65\u201374."},{"key":"717_CR23","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar3908","volume":"15","author":"MJ Leandro","year":"2013","unstructured":"Leandro MJ. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res Ther. 2013;15:S3.","journal-title":"Arthritis Res Ther"},{"key":"717_CR24","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1186\/ar2798","volume":"11","author":"M Nakou","year":"2009","unstructured":"Nakou M, Katsikas G, Sidiropoulos P, Bertsias G, Papadimitraki E, Raptopoulou A, et al. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther. 2009;11:R131.","journal-title":"Arthritis Res Ther"},{"key":"717_CR25","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1002\/art.30599","volume":"63","author":"J Sellam","year":"2011","unstructured":"Sellam J, Rouanet S, Hendel-Chavez H, Abbed K, Sibilia J, Tebib J, et al. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2011;63:3692\u2013701.","journal-title":"Arthritis Rheum"},{"key":"717_CR26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/cei.12481","volume":"180","author":"AP Trouvin","year":"2015","unstructured":"Trouvin AP, Jacquot S, Grigioni S, Curis E, Dedreux I, Roucheux A, et al. Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study. Clin Exp Immunol. 2015;180:11\u20138.","journal-title":"Clin Exp Immunol"},{"key":"717_CR27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nri3128","volume":"12","author":"M McHeyzer-Williams","year":"2012","unstructured":"McHeyzer-Williams M, Okitsu S, Wang N, McHeyzer-Williams L. Molecular programming of B cell memory. Nat Rev Immunol. 2012;12:24\u201334.","journal-title":"Nat Rev Immunol"},{"key":"717_CR28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1600-065X.2010.00938.x","volume":"237","author":"T Yoshida","year":"2010","unstructured":"Yoshida T, Mei H, Dorner T, Hiepe F, Radbruch A, Fillatreau S, et al. Memory B and memory plasma cells. Immunol Rev. 2010;237:117\u201339.","journal-title":"Immunol Rev"},{"key":"717_CR29","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/nri3802","volume":"15","author":"T Kurosaki","year":"2015","unstructured":"Kurosaki T, Kometani K, Ise W. Memory B cells. Nat Rev Immunol. 2015;15:149\u201359.","journal-title":"Nat Rev Immunol"},{"key":"717_CR30","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4049\/jimmunol.180.1.361","volume":"180","author":"DJ DiLillo","year":"2008","unstructured":"DiLillo DJ, Hamaguchi Y, Ueda Y, Yang K, Uchida J, Haas KM, et al. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol. 2008;180:361\u201371.","journal-title":"J Immunol"},{"key":"717_CR31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/cei.12390","volume":"178","author":"J Westra","year":"2014","unstructured":"Westra J, van Assen S, Wilting KR, Land J, Horst G, de Haan A, et al. Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients. Clin Exp Immunol. 2014;178:40\u20137.","journal-title":"Clin Exp Immunol"},{"key":"717_CR32","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3109\/03009748809096769","volume":"75","author":"I Teitsson","year":"1988","unstructured":"Teitsson I. IgA rheumatoid factor as predictor of disease activity. Scand J Rheumatol Suppl. 1988;75:233\u20137.","journal-title":"Scand J Rheumatol Suppl"},{"key":"717_CR33","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1002\/art.11223","volume":"48","author":"S Rantapaa-Dahlqvist","year":"2003","unstructured":"Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48:2741\u20139.","journal-title":"Arthritis Rheum"},{"key":"717_CR34","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2006.060608","volume":"66","author":"F Bobbio-Pallavicini","year":"2007","unstructured":"Bobbio-Pallavicini F, Caporali R, Alpini C, Avalle S, Epis OM, Klersy C, et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis. 2007;66:302\u20137.","journal-title":"Ann Rheum Dis"},{"key":"717_CR35","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/rheumatology\/ker417","volume":"51","author":"I Torre De La","year":"2012","unstructured":"De La Torre I, Leandro MJ, Valor L, Becerra E, Edwards JC, Cambridge G. Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics. Rheumatology. 2012;51:833\u201340.","journal-title":"Rheumatology"},{"key":"717_CR36","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1182\/blood-2008-04-153544","volume":"113","author":"HE Mei","year":"2009","unstructured":"Mei HE, Yoshida T, Sime W, Hiepe F, Thiele K, Manz RA, et al. Blood-borne human plasma cells in steady state are derived from mucosal immune responses. Blood. 2009;113:2461\u20139.","journal-title":"Blood"},{"key":"717_CR37","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1182\/blood-2010-01-266536","volume":"116","author":"HE Mei","year":"2010","unstructured":"Mei HE, Frolich D, Giesecke C, Loddenkemper C, Reiter K, Schmidt S, et al. Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab. Blood. 2010;116:5181\u201390.","journal-title":"Blood"},{"key":"717_CR38","first-page":"371","volume":"386","author":"H Hasegawa","year":"2015","unstructured":"Hasegawa H, van Reit E, Kida H. Mucosal immunization and adjuvants. Curr Top Microbiol Immunol. 2015;386:371\u201380.","journal-title":"Curr Top Microbiol Immunol"},{"key":"717_CR39","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s11926-014-0408-9","volume":"16","author":"J Koziel","year":"2014","unstructured":"Koziel J, Mydel P, Potempa J. The link between periodontal disease and rheumatoid arthritis: an updated review. Curr Rheumatol Rep. 2014;16:408.","journal-title":"Curr Rheumatol Rep"},{"key":"717_CR40","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1016\/j.febslet.2014.05.034","volume":"588","author":"V Taneja","year":"2014","unstructured":"Taneja V. Arthritis susceptibility and the gut microbiome. FEBS Lett. 2014;588:4244\u20139.","journal-title":"FEBS Lett"},{"key":"717_CR41","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1136\/gut.2005.076901","volume":"55","author":"M Hvatum","year":"2006","unstructured":"Hvatum M, Kanerud L, Hallgren R, Brandtzaeg P. The gut-joint axis: cross reactive food antibodies in rheumatoid arthritis. Gut. 2006;55:1240\u20137.","journal-title":"Gut"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0717-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T04:17:54Z","timestamp":1653020274000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.com\/content\/17\/1\/206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,13]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["717"],"URL":"https:\/\/doi.org\/10.1186\/s13075-015-0717-z","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,13]]},"article-number":"206"}}